Drugs / PERFLENAPENT
PERFLENAPENT
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | EchoGen | — | 2001-01-22 | europa.eu ↗ |
| Approved | EU (EMA) | EchoGen | — | 1998-07-17 | europa.eu ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06658535 | Mar 2025 → Dec 2026 expected | — | NuvOx LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT02189109 | May 2014 → Aug 2017 | glioblastoma | NuvOx LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-04-30 | NuvOx LLC | Results NuvOx Announces Positive Completion of 2nd Cohort in its EXTEND-1b Trial and Presentation at RIS nuvoxtherapeutics.com ↗
Preliminary analysis from the second cohort demonstrated statistically significant improvement in arterial oxygenation measured by arterial blood gas, along with improved pulse oximetry readings, supporting a clear dose-response relationship and stronger efficacy signals at the higher dose. |
| 2026-03-05 | NuvOx LLC | Regulatory FDA Permits NuvOx Therapeutics to Initiate Phase II REBORN Trial of NanO2 in Recurrent High-Grade Glioma nuvoxtherapeutics.com ↗ |
| 2025-11-26 | NuvOx LLC | Results NuvOx and Dr. Pavani Chalasani Announce acceptance of abstracts in Triple Negative Breast Cancer at 2 prestigious conventions - “Novel Oxygen Therapeutic Shows Promise in Boosting Immunotherapy” nuvoxtherapeutics.com ↗
The studies also found that combining NanO₂ with oxygen exposure, immunotherapy, or chemotherapy further enhanced these immune and anti-tumor effects. |
| 2025-11-07 | NuvOx LLC | Results NuvOx Therapeutics Announces Positive Results from First Cohort of EXTEND-1b Trial of NanO₂™ in Patients with Respiratory Distress nuvoxtherapeutics.com ↗
NanO₂ was well tolerated in all participants, with no drug-related serious adverse events. |
| 2025-02-12 | NuvOx LLC | Regulatory NuvOx Announces MHRA Approval to Commence Phase IIb Stroke Trial nuvoxtherapeutics.com ↗
NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom in collaboration with the Research Ethics Committee has accepted the amended request for a clinical trial authorisation (CTA). |
| 2024-10-28 | NuvOx LLC | Results NuvOx Announces Two New Publications nuvoxtherapeutics.com ↗
Artificial Cells, Nanomedicine, and Biotechnology published Dodecafluoropentane emulsion as an oxygen therapeutic , an article that explains NanO2’s mechanism of action of delivering oxygen. |
| 2024-07-11 | NuvOx LLC | Regulatory NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada nuvoxtherapeutics.com ↗
NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND : nov E l o X ygen T h E rapeutic N anO2 for mild respiratory distress in Phase Ib and AR D S in Phase II Trials |
| 2023-08-30 | NuvOx LLC | Results NuvOx Announces Publication of Research Article in Cancer Research Communication nuvoxtherapeutics.com ↗
The data showed increase in overall survival and progression free survival compared to historical control. |
| 2002-07-01 | NuvOx LLC | Results Radiosensitization of hypoxic tumor cells by DDFPe nuvoxtherapeutics.com ↗
DDFPe plus carbogen appears to completely reverse the hypoxic cell radioresistance in this tumor model. |
| 2001-04-27 | NuvOx LLC | Results Human pharmacokinetics of a DDFPe with gas chromatography nuvoxtherapeutics.com ↗
It was concluded that DDFP pharmacokinetics in blood has fast elimination. |
All press releases naming this drug 14 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERFLENAPENT | ChEMBL registry synonym — accepted as the source's own label CHEMBL1899801 ↗ |
| Known as | dodecafluoropentane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06658535 ↗ |
| Known as | Echogen | ChEMBL registry synonym — accepted as the source's own label CHEMBL1899801 ↗ |
| Known as | FC41-12 (PERFLENAPENT/PERFLISOPENT MIXTURE) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1899801 ↗ |
| Known as | NVX-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02189109 ↗ |
| Modality | Small molecule | — CHEMBL1899801 ↗ |
| Route | Intravenous | “sustained IV infusion of 0.375 mL/kg over 21 hours.” NCT06658535 ↗ |